STOCK TITAN

Moleculin Biotech Inc - MBRX STOCK NEWS

Welcome to our dedicated news page for Moleculin Biotech (Ticker: MBRX), a resource for investors and traders seeking the latest updates and insights on Moleculin Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Moleculin Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Moleculin Biotech's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
conferences earnings
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.45%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.45%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.37%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
none
Moleculin Biotech Inc

Nasdaq:MBRX

MBRX Rankings

MBRX Stock Data

13.16M
1.93M
4.65%
15.54%
0.09%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Houston

About MBRX

moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml. we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. the other portfolio targets the metabolism of tumors.